Section Arrow
Quote
GYRE.NASDAQ
- Gyre Therapeutics
Quotes are at least 15-min delayed:2025/11/16 13:32 EST
Regular Hours
Last
 7.99
-0.09 (-1.11%)
Day High 
8.225 
Prev. Close
8.08 
1-M High
9.42 
Volume 
64.15K 
Bid
7.99
Ask
8.25
Day Low
7.8219 
Open
7.94 
1-M Low
7.12 
Market Cap 
778.37M 
Currency USD 
P/E 202 
%Yield 46.94 
10-SMA 7.67 
20-SMA 7.84 
50-SMA 7.75 
52-W High 14.4228 
52-W Low 6.11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.04/0.10
Enterprise Value
779.26M
Balance Sheet
Book Value Per Share
1.06
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
105.76M
Operating Revenue Per Share
1.05
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 13:32 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenuefrom the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.